|                   | Breakthrough                                 |                           |          |           |                 |              |                              |              |          | A description of the                              |                             |
|-------------------|--|---------------------------|----------|-----------|-----------------|--------------|------------------------------|--------------|----------|---|-----------------------------|
|                   |  |                           |          | Pack      | WAC (as of date | Date of      |                              | therapy      | Priority |   | marketing and pricing plans |
|                   |  |                           |          | Size/Volu | of commercial   | Commercial   | Estimated volume of patients | designation? | Review?  | Date and price of acquisition if the drug was not | used in the launch of the   |
| Manufacturer Name | NDC  | Name of Prescription Drug | Strength | me        | availability)   | Availability | who may be prescribed drug   | (Y/N)        | (Y/N)    | developed by the manufacturer else N/A            | new drug                    |
|                   | 81964000354                                  |                           |          |           |                 |              | Information Not Publicly     |              |          |   | Information Not Publicly    |
| USAntibiotics     | AUGMENTIN ES-600 - amoxicil 600mg-42.5mg/5ml |                           |          | 200ml     | \$915.36        | 4/29/2023    | Available                    | N            | N        | Acquired in 2021 as part of a company acquisition | Available                   |